Improvements in Patient-Reported Outcomes in Relapsed or Refractory Large B-Cell Lymphoma Patients Treated With Epcoritamab.

Autor: Phillips T; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI. Electronic address: tphillips@coh.org., Lugtenburg P; On behalf of the Lunenburg Lymphoma Phase I/II Consortium-HOVON/LLPC, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands., Kalsekar A; Genmab, Plainsboro, NJ., Mutebi A; Genmab, Plainsboro, NJ., Wang A; AbbVie, North Chicago, IL., Blaedel J; Genmab, Plainsboro, NJ., Kosa K; RTI Health Solutions, Ann Arbor, MI., Martin S; RTI Health Solutions, Ann Arbor, MI., Sacchi M; Genmab, Plainsboro, NJ., Kilavuz N; Genmab, Plainsboro, NJ., Thieblemont C; Assistance Publique & Hôpitaux de Paris (APHP), Hôpital Saint-Louis, Hémato-Oncologie, Université de Paris, Paris, France.
Jazyk: angličtina
Zdroj: Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2024 Mar; Vol. 24 (3), pp. e78-e87.e2. Date of Electronic Publication: 2023 Nov 27.
DOI: 10.1016/j.clml.2023.11.005
Abstrakt: Background: Patient-reported outcomes were evaluated in EPCORE NHL-1 in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) treated with epcoritamab monotherapy (NCT03625037).
Materials and Methods: Adults with R/R CD20 + LBCL and ≥2 prior systemic antilymphoma therapies, including anti-CD20, completed the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) and EQ-5D-3L. A subgroup of patients provided additional feedback in one-on-one qualitative interviews. FACT-Lym and EQ-5D-3L score changes from baseline (CFB) to cycle 9 or end of treatment were interpreted using published minimally important differences (MID).
Results: In total, 157 patients (88.5% with diffuse LBCL) were treated (median age, 64 years). In total, 70.7% had ≥3 prior treatments, 61.1% had primary refractory disease, and 82.8% were refractory to last systemic therapy. FACT-Lym scores exceeded MID thresholds: mean (SD) CFB were 4.4 (15.2), MID 3.0 to 7.0 (FACT-General); 5.9 (7.6), MID 2.9 to 5.4 (FACT-Lymphoma subscale); 8.4 (15.2), MID 5.5 to 11.0 (FACT-Trial Outcome Index); 10.3 (20.2), MID 6.5 to 11.2 (FACT-Lym total score). EQ-5D-3L index scores, 0.09 (0.20), MID 0.08, and EQ-VAS scores, 16.6 (22.8), MID 7.0, improved. In 20 qualitative interviews, 88.2% reported symptom improvements; 80.0% were "very satisfied" or "satisfied" with epcoritamab.
Conclusions: R/R LBCL patients reported consistent, clinically meaningful improvements in symptoms and HRQoL and satisfaction with epcoritamab.
Competing Interests: Disclosure Tycel Phillips: Seattle Genetics, Pharmacyclics, Incyte, Genentech, Bayer, Gilead Sciences, Curis, Kite/Gilead, Celgene, Genmab, TG Therapeutics, ADC Therapeutics: Consulting or Advisory Role; Seattle Genetics, Lymphoma & Myeloma Connect: Honoraria; AbbVie, Pharmacyclics/Janssen, Bayer: Research Funding; The Leukemia & Lymphoma Society: Scholar in Clinical Research; Pieternella Lugtenburg: Takeda, Servier: Research Grants; Celgene, Roche, Takeda, Genmab, AbbVie, Incyte, Regeneron: Advisory Honoraria. Y-mAbs Therapeutics: Consultancy Honoraria; Lilly: Speakers Bureau; Anupama Kalsekar: Employee of Genmab; Alex Mutebi: Employee of Genmab; Anthony Wang: Employee of AbbVie; Julie Blaedel: Employee of Genmab; Katherine Kosa: Employee of RTI Health Solutions who received funding from Genmab for the design, conduct, and analysis of the qualitative interviews; Susan Martin: Employee of RTI Health Solutions who received funding from Genmab for the design, conduct, and analysis of the qualitative interviews; Mariana Sacchi: Employee of Genmab; Nurgul Kilavuz: Employee of Genmab; Catherine Thieblemont: BMS/Celgene, Hospira, Roche: Research Funding; AbbVie, Amgen, BMS/Celgene, Cellectis, Gilead Sciences, Kite, Novartis, Roche: Consultancy; AbbVie, Amgen, Bayer, Cellectis, Gilead Sciences, Incyte, Janssen, Kite, Novartis, Takeda: Honoraria; AbbVie, Amgen, BMS/Celgene, Cellectis, Gilead Sciences, Incyte, Janssen, Kite, Novartis, Roche, Takeda: Membership on an Entity's Board of Directors or Advisory Committees; AbbVie, Amgen, BMS/Celgene, Cellectis, Gilead Sciences, Kite, Novartis, Roche: Travel, Accommodations, Expenses.
(Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: